Table 1.

Stroke Therapy Academic Industry Roundtable (STAIR) quality of telmisartan, irbesartan, and candesartan.

Item	Description	Telmisartan	Irbesartan	Candesartan
Laboratory setting	Focal model tested in two or more laboratories	√	√	√
Animal species	Focal model tested in two or more species	√	√	√
Health of animals	Focal model tested in old or diseased animals (e.g., diabetic, hypertensive, aged, and hyperglycemic)	√	√	√
Sex of animals	Focal model tested in male and female animals	×	×	×
Reperfusion	Tested in temporary and permanent models of focal ischemia	√	√	√
Time window	Drug administered at least 1 h after occlusion in focal model	×	×	√
Dose response	Drug administered using at least two doses in focal model	√	√	√
Route of delivery	Tested using a feasible mode of delivery (e.g., not intracisternal or intraventricular, cortical transplant or graft only)	×	×	×
Endpoint	Behavioral and histological outcomes measured	√	√	√
Long-term effect	Outcome measured at 4 or more weeks after occlusion in focal models	√	×	×
Total		7	6	7

The number of STAIR criteria met by the drug (maximum: 10) are listed.